Evidence summaries and landmark trials across type 1, type 2, prevention, glycaemic control, complications, and diabetes technology.
A prespecified DARE-19 analysis found dapagliflozin was safe and well tolerated in hospitalised COVID-19 patients regardless of type 2 diabetes status, with no demonstrated efficacy benefit. PICO summary and expert commentary.
A double-blind RCT finds empagliflozin gives broader cardiometabolic benefit than sitagliptin or metformin as add-on therapy in type 2 diabetes. PICO summary and commentary.
An RCT finds a periodontal health programme improves oral hygiene and knowledge in older diabetic patients, but not oral-health quality of life. PICO summary and commentary.
A machine-learning analysis finds lower baseline periodontal severity and HbA1c predict better response to gum therapy in diabetes (random forest AUC 0.83). PICO summary and commentary.
A multicentre RCT finds a CBT-based dietary app improves postprandial glucose and reduces macrosomia in gestational diabetes. PICO summary and commentary.
A post-hoc analysis of 307 ACCORD-BP participants with type 2 diabetes and prior stroke links intensive systolic blood pressure control to fewer cardiovascular events. PICO summary and expert commentary.
Welcome to Hormone Insight. Our mission is to support clinical decision-making with accessible, evidence-based insights from recent studies and trials.
© 2024-2026 Hormone Insight. All rights reserved.
